U.S. federal trademark · Serial No. 88165624
Research and development services in the field of boron neutron capture therapy (BNCT) for solid tumor oncology, provided exclusively to particle accelerator operators, research reactor facilities, and specialized institutional oncology partners; all the foregoing excluding research and development in the field of ophthalmology
Boronated chemical compounds for use exclusively in the manufacture of target drugs for boron neutron capture therapy (BNCT) solid tumor radiation therapy; all the foregoing excluding ophthalmic products, topical formulations, and general pharmaceutical compounds
Biological and pharmaceutical preparations for the targeted treatment of solid-tumor cancers via high-dose thermal neutron irradiation in boron neutron capture therapy (BNCT), distributed exclusively to licensed nuclear medicine treatment facilities, particle accelerator cancer therapy centers, and hospital radiation oncology departments; all the foregoing excluding ophthalmic treatments, eye drops, and general retail pharmaceutical trade channels
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.